X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA JUBILANT LIFE SCIENCES ALEMBIC PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 28.6 27.4 104.2% View Chart
P/BV x 6.5 5.6 115.8% View Chart
Dividend Yield % 0.7 0.3 223.7%  

Financials

 ALEMBIC PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
ALEMBIC PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs792187 423.8%   
Low Rs44365 680.5%   
Sales per share (Unadj.) Rs167.0364.3 45.8%  
Earnings per share (Unadj.) Rs38.26.8 557.5%  
Cash flow per share (Unadj.) Rs42.024.5 171.4%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.62.4 27.2%  
Book value per share (Unadj.) Rs84.9164.9 51.5%  
Shares outstanding (eoy) m188.52159.28 118.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.70.3 1,069.2%   
Avg P/E ratio x16.218.4 87.9%  
P/CF ratio (eoy) x14.75.1 286.0%  
Price / Book Value ratio x7.30.8 952.0%  
Dividend payout %10.543.8 23.9%   
Avg Mkt Cap Rs m116,38320,061 580.1%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m4,21411,052 38.1%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m31,48758,034 54.3%  
Other income Rs m55191 28.9%   
Total revenues Rs m31,54258,224 54.2%   
Gross profit Rs m10,0605,786 173.9%  
Depreciation Rs m7222,812 25.7%   
Interest Rs m373,237 1.1%   
Profit before tax Rs m9,356-72 -12,976.4%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m2,160696 310.2%   
Profit after tax Rs m7,1941,090 659.8%  
Gross profit margin %31.910.0 320.4%  
Effective tax rate %23.1-965.9 -2.4%   
Net profit margin %22.81.9 1,216.0%  
BALANCE SHEET DATA
Current assets Rs m15,06629,280 51.5%   
Current liabilities Rs m7,67438,912 19.7%   
Net working cap to sales %23.5-16.6 -141.4%  
Current ratio x2.00.8 260.9%  
Inventory Days Days6784 79.4%  
Debtors Days Days4151 80.2%  
Net fixed assets Rs m8,23755,712 14.8%   
Share capital Rs m377155 244.0%   
"Free" reserves Rs m15,41620,968 73.5%   
Net worth Rs m16,00526,265 60.9%   
Long term debt Rs m017,169 0.0%   
Total assets Rs m24,59488,606 27.8%  
Interest coverage x255.21.0 26,105.3%   
Debt to equity ratio x00.7 0.0%  
Sales to assets ratio x1.30.7 195.5%   
Return on assets %29.44.9 602.0%  
Return on equity %44.94.2 1,082.7%  
Return on capital %58.711.6 507.3%  
Exports to sales %55.737.8 147.5%   
Imports to sales %10.416.5 63.2%   
Exports (fob) Rs m17,55121,933 80.0%   
Imports (cif) Rs m3,2839,567 34.3%   
Fx inflow Rs m17,81122,004 80.9%   
Fx outflow Rs m5,31811,749 45.3%   
Net fx Rs m12,49310,255 121.8%   
CASH FLOW
From Operations Rs m9,3048,026 115.9%  
From Investments Rs m-3,105-1,744 178.0%  
From Financial Activity Rs m-1,959-4,447 44.1%  
Net Cashflow Rs m4,2401,834 231.1%  

Share Holding

Indian Promoters % 74.1 45.6 162.5%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 2.9 8.7 33.3%  
FIIs % 9.1 21.2 42.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.1 65.9%  
Shareholders   49,328 23,815 207.1%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - DISHMAN PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS